Biclotymol

Biclotymol is an antimicrobial agent and a compound with inhibitory activity against Gram-positive cocci, with an MIC of 150 μM against Streptococcus pneumoniae and Haemophilus influenzae. This compound possesses anti-inflammatory, analgesic, and cell permeability properties, and is used in research related to ear-nose-throat infections and throat pain.

Methods: The minimum inhibitory concentration (MIC) and bactericidal kinetics of Biclotymol against various respiratory pathogens were determined through in vitro antimicrobial assays.
Results: Biclotymol demonstrated the highest sensitivity against Streptococcus pneumoniae and Haemophilus influenzae (MIC = 0.15 mg/mL), exhibiting rapid bactericidal activity within less than 1 minute of exposure at 20 mg/mL in a dose-dependent manner.[1]

Methods: Two clinical trials were conducted in patients with acute pharyngitis. An open-label trial (n=40) compared Biclotymol spray (3 times daily, 2 sprays each time) with Fusafungine (4 times daily, 4 sprays each time) for 7-10 days; a double-blind trial (n=39) compared Biclotymol spray (3 times daily, 2 sprays each time) with placebo for 4-8 days.
Results: In the Biclotymol group, 50% (acute) and 34.5% (chronic) of patients rated efficacy as "good/very good," superior to Fusafungine; 80% of patients rated efficacy as "good/very good," with 65% achieving complete pain relief, significantly outperforming placebo. [1]